Loading stock data…
JYNT
$8.90+0.03 (+0.34%)
Market ClosedLast close May 1
The Joint Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Joint Corp. in the Healthcare sector is trading at $8.90. The stock is currently 34% below its 52-week high of $13.47, remaining 4.2% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why JYNT maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.90
Potential Upside
5%
Whystock Fair Value$9.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
The Joint Corp. operates and is a franchisor and operator of chiropractic clinics in the United States. The company provides services under the franchise agreement, including training of franchisees and staff, site selection, construction/vendor mana...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$126.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.01%
Volume
Today's trading volume
47,967
Recent News
Loss-Making The Joint Corp. (NASDAQ:JYNT) Set To Breakeven
With the business potentially at an important milestone, we thought we'd take a closer look at The Joint Corp.'s...
The Joint Corp. Q4 2025 Earnings Call Summary
Moby summary of The Joint Corp.'s Q4 2025 earnings call
The Joint Corp (JYNT) Q4 2025 Earnings Call Highlights: Strategic Refranchising and Marketing ...
The Joint Corp (JYNT) reports revenue growth and strategic shifts, despite facing hurdles in patient acquisition and sales comps.
Joint Q4 Earnings Call Highlights
Joint (NASDAQ:JYNT) reported fourth-quarter and full-year 2025 results while outlining progress on its “Joint 2.0” transformation plan, which management said is on track to be completed by the end of 2026. On the company’s earnings call, President and CEO Sanjiv Razdan and CFO Scott Bowman highlight
The Joint (JYNT) Q4 2025 Earnings Call Transcript
Joining us on the call today are President and CEO, Sanjiv Razdan, and CFO, Scott Bowman. This afternoon, The Joint Corp. issued a press release for the fourth quarter and full year ended 12/31/2025. As provided on Slide 2, please be advised that today’s discussion, including any financial and related guidance to be provided, consists of forward-looking statements as defined by securities laws.